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LETTERS
Patients admitted to the hospital 
with pulmonary inﬁ  ltrates were em-
pirically treated with high dose oselta-
mivir (150 mg 2×/d) for 5 days, other 
antimicrobial drugs, and, eventually, 
steroids. In 2 patients, the respira-
tory disease progressed initially but 
they eventually recovered; 2 patients 
(1.2% of admissions to hospital) with 
acute respiratory failure died. Despite 
improvement in clinical symptoms 
at discharge, chest radiographs per-
formed on a limited number of pa-
tients showed no substantial changes 
at 72–96 h after admission.
Clinical manifestations of pan-
demic (H1N1) 2009 have not yet been 
fully characterized. We observed a 
mild to moderate lower respiratory 
disease in ≈8% of consecutive patients 
with ILI during the current pandemic 
in Argentina. A more severe respira-
tory disease was observed in Mexico 
during the current pandemic (4) In 
contrast, early reports indicated that 
pandemic (H1N1) 2009 disease might 
be similar in severity to seasonal inﬂ  u-
enza (3). A lack of microbiologic con-
ﬁ   rmation may bias our observation. 
Because pulmonary inﬁ  ltrates are un-
common in previously healthy persons 
with ILI, a simultaneous circulation of 
other respiratory pathogens may ex-
plain our observation. Furthermore, 
early empirical use of antimicrobial 
drugs could overshadow clinical fea-
tures of bacterial pneumonia.
We observed an unexpectedly 
high rate of lower respiratory disease 
in adults with ILI during an outbreak 
of pandemic (H1N1) 2009 in Argenti-
na. This ﬁ  nding suggests that a unique 
pattern of virulence, pulmonary tro-
pism, or both may characterize the 
current inﬂ  uenza A (H1N1) infection, 
although we could not rule out co-in-
fection with other viral or bacterial re-
spiratory pathogens. Considering the 
evolving nature of inﬂ  uenza viruses, 
the wide clinical spectrum of pan-
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Susceptibility of 
Poultry to Pandemic 
(H1N1) 2009 Virus
To the Editor: During April 
2009, cases of acute respiratory dis-
ease in humans caused by inﬂ  uenza 
A pandemic (H1N1) 2009 virus in 
Mexico were reported (1). By Au-
gust 21, 2009, a total of >182,166 
human cases, including 1,799 deaths, 
had been reported from 177 countries 
(www.who.int/csr/don/2009_08_21/
en/index.html). 
The origin of the new virus ap-
pears to be a reassortant event of a 
virus from swine in North America 
that contained the classic swine, hu-
man, and avian inﬂ  uenza genes and a 
virus of unknown origin that contrib-
uted neuraminidase and matrix genes 
of swine in Europe. On May 2, 2009, 
the ﬁ  rst nonhuman infections were de-
tected in a swine operation in Canada 
(www.who.int/csr/don/2009_06_24/
en/index.html).
Historically, human seasonal in-
ﬂ  uenza A viruses have not been report-
ed to infect poultry, but clinical cases 
of respiratory disease or reduction in 
egg production have been reported for 
domestic turkeys after infection with 
subtypes H1N1, H1N2, and H3N2 
swine inﬂ  uenza viruses and for mul-
tiple poultry species with subtype 
H1N1 avian inﬂ   uenza virus (2–4). 
The presence of avian and swine inﬂ  u-
enza virus genes in pandemic (H1N1) 
2009 virus increases the potential for 
infection in poultry after exposure to 
infected humans or swine.
To determine infectivity potential, 
3-week-old chickens (Gallus domes-
ticus) (n = 11), 2-week-old domestic 
ducks (Anas platyrhynchos) (n = 11), 
73-week-old reproductively active 
turkey hens (Meleagris gallopavo) (n 
= 9), 3-week-old turkey poults (n = 
11), and 5-week-old Japanese quail 
(Coturnix japonica) (n = 11) were 
intranasally inoculated with 106 mean 
chicken embryo infectious doses of 
A/Mexico/4108/2009(H1N1). Five 
uninfected chickens, ducks, turkey 
poults, and quail, and 3 uninfected 
turkey hens were contact exposed to 
intranasally inoculated birds to as-
sess transmission potential. Cloacal 
and oropharyngeal swabs were taken 
on 2, 4, 7, and 10 days postinocula-
tion (DPI) from all birds, and internal 
tissues were taken from 2 birds on 2, 
4 and 7 DPI for virus detection by 
quantitative real-time reverse tran-
scription–PCR (qRRT-PCR) assay 
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speciﬁ  c for the inﬂ  uenza virus matrix 
gene (5).
To improve sensitivity because 
of several primer mismatches, we 
updated the reverse primer to 3′-
CAGAGACTGGAAAGTGTCTTT
GCA-5′. Virus isolation in embryonat-
ing chicken eggs was used on a sub-
set of samples to verify qRRT-PCR 
results at 4 DPI. Serum samples were 
collected on 15 DPI for antibody test-
ing by hemagglutination inhibition. 
Shams were intranasally inoculated 
with culture media and sampled on 
4 and/or 7 DPI. We inoculated ten 4 
week-old chickens intravenously to 
determine pathotype by using the in-
travenous pathogenicity index (IVPI). 
All animal studies were conducted un-
der BioSafety Level 3 enhanced con-
ditions with approval by Institutional 
Animal Care and Use and BioSafety 
committees.
During the 15-day observation 
period, clinical signs did not develop 
in any of the birds; none of the birds 
died. An IVPI of 0.00 indicated the vi-
rus was not of high pathogenicity for 
chickens. No virus was detected by 
qRRT-PCR or isolated in chicken eggs 
from swabs or tissues from chickens, 
turkeys, or ducks. All chickens and 
turkeys were negative for antibodies to 
the virus on 15 DPI, but 1 intranasally 
inoculated duck had a hemagglutina-
tion inhibition (HI) antibody titer of 
16. Virus was detected in oropharyn-
geal swabs at 2 and 4 DPI from intra-
nasally (IN)–inoculated quail (Table), 
and these quail had antibodies against 
inﬂ  uenza A at 15 DPI. The intranasally 
inoculated quail had heterophilic-to-
lymphocytic rhinitis, and inﬂ  uenza 
virus was visualized by immunohis-
tochemical analysis of epithelium and 
macrophages within the mucosa of the 
nasal cavity; neither lesions nor anti-
gen were identiﬁ  ed in other respira-
tory and nonrespiratory tissues. Virus 
was not isolated from contact-exposed 
quail (Table), and they lacked antibod-
ies on 15 DPI.
Infection with swine inﬂ  uenza 
viruses in turkeys has been frequently 
reported, and experimental intrana-
sal inoculation studies using 5 such 
viruses have produced infection and 
disease with associated contact trans-
mission to uninfected turkeys (3,4,6). 
However, infection of chickens by 
swine inﬂ  uenza viruses has been rare 
in the ﬁ  eld, and experimental studies 
have shown limited respiratory repli-
cation after intranasal inoculation but 
no transmission (3,6–8). Experimental 
inoculation of ducks failed to produce 
infection or transmission (8).
Recently, subtype H3N2 swine 
inﬂ  uenza A virus infection with respi-
ratory disease in Japanese quail has 
been reported in Canada, and such 
infections have been experimentally 
reproduced by intranasal inoculation 
(9,10). However, in our studies, pan-
demic (H1N1) 2009 virus was bio-
logically distinct from swine inﬂ  uenza 
viruses, failing to produce infection in 
experimentally inoculated turkey hens 
or chickens, and only 1 serologically 
positive IN-inoculated domestic duck. 
In addition, Japanese quail were in-
fected by high dose IN exposure, but 
replication and shedding was limited 
to the respiratory tract, and the virus 
did not transmit to quail by contact, 
suggesting low potential of poultry in-
volvement as an ampliﬁ  cation host for 
current pandemic (H1N1) 2009 virus. 
Pandemic (H1N1) 2009 virus is un-
likely to produce sustained outbreaks 
in poultry unless the virus mutates or 
reassorts with existing avian inﬂ  uenza 
viruses. Since the submission of this 
report, the virus has been detected in 
2 turkey ﬂ   ocks in Chile (www.oie.
int/wahis,/public.php?page=single_
report&pop=1&reportid=8404). Cur-
rently, only limited data are available, 
and it is unknown if pandemic (H1N1) 
2009 has changed and acquired the 
ability to infect and transmit in turkeys 
or if the 2 cases are isolated events 
without epidemic potential in turkeys. 
Acknowledgments
We thank Joan R. Beck, James Doster, 
Kira Moresco, Scott Lee, and Suzanne 
Dublois for technical assistance. 
This research was supported by US 
Department of Agriculture Current Re-
search Information System project 6612-
32000-048-00D. 




and David L. Suarez
Author afﬁ  liation: US Department of Agricul-
ture, Athens, Georgia, USA
References
  1.   Garten RJ, Davis CT, Russell CA, Shu B, 
Lindstrom S, Balish A, et al. Antigenic 
and genetic characteristics of swine-origin 
2009 A(H1N1) inﬂ  uenza viruses circulat-
ing in humans. Science. 2009;329:197–
201.
  2.   Suarez  DL,  Woolcock  PR,  Bermudez 
AJ, Senne DA. Isolation from turkey 
breeder hens of a reassortant H1N2 
inﬂ   uenza virus with swine, human, 
and avian lineage genes. Avian Dis. 
2002;46:111–21. DOI: 10.1637/0005-
2086-2002)046[0111:IFTBHO]2.0.CO;2
    3.    Pillai SPS, Pantin-Jackwood M, Jadhao 
SJ, Suarez DL, Wang L, Yassine HM, et al. 
Pathobiology of triple reassortant H3N2 
inﬂ  uenza viruses in breeder turkeys and 
its potential implication for vaccine stud-
ies in turkeys. Vaccine. 2009;27:819–24. 
DOI: 10.1016/j.vaccine.2008.11.076
2062  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 12, December 2009
Table. Results of testing for influenza A pandemic (H1N1) 2009 virus in oropharyngeal 
swabs of experimental quail  
Sampling day (days postinoculation) for oropharyngeal swab* 
Group  247 1 0
Intranasally inoculated  2/5 (10
0.9)5 / 5  ( 1 0
2.8) 0/5 0/5
Contact 0/5 0/5 0/5 0/5
*Number virus positive/total sampled (average titer of positive samples, mean chicken embryo 
infectious doses). Test results for all cloacal swabs were negative. LETTERS
  4.   Kapczynski DR, Gonder E, Liljebjelke K, 
Lippert R, Petkov D, Tilley B. Vaccine-
induced protection from egg production 
losses in commercial turkey breeder hens 
following experimental challenge with a 
triple-reassortant H3N2 avian inﬂ  uenza 
virus. Avian Dis. 2009;53:7–15. DOI: 
10.1637/8199-122707-Reg.1
  5.   Spackman E, Senne DA, Myers TJ, Bulaga 
LL, Garber LP, Perdue ML, et al. Devel-
opment of a real-time reverse transcriptase 
PCR assay for type A inﬂ  uenza virus and 
the avian H5 and H7 hemagglutinin sub-
types. J Clin Microbiol. 2002;40:3256–60. 
DOI: 10.1128/JCM.40.9.3256-3260.2002
    6.    Senne DA. Annual reports on National 
Veterinary Services Laboratories avian 
inﬂ   uenza and Newcastle disease virus 
diagnostics. Proceedings of the Unit-
ed States Animal Health Association. 
2006;110:634–7.
  7.   Thomas  C,  Manin  TB,  Andriyasov 
AV, Swayne DE. Limited susceptibil-
ity and lack of systemic infection by an 
H3N2 swine inﬂ   uenza virus in intrana-
sally inoculated chickens. Avian Dis. 
2008;52:498–501. DOI: 10.1637/8210-
011408-RESNOTE.1
  8.   Yassine HM, Al Natour MQ, Lee C, Saif 
YM. Interspecies and intraspecies trans-
mission of triple reassortant H3N2 inﬂ  u-
enza A viruses. Virol J. 2007;4:129. DOI: 
10.1186/1743-422X-4-129
  9.   Choi YK, Lee JH, Erickson G, Goyal SM, 
Joo HS, Webster RG, et al. H3N2 inﬂ  u-
enza virus transmission from swine to 
turkeys, United States. Emerg Infect Dis. 
2004;10:2156–60.
10.   Senne DA. Avian inﬂ  uenza in North and 
South America, the Caribbean, and Aus-
tralia, 2006–2008. Avian Dis. 2009. In 
press. 
Address for correspondence: David E. Swayne, 
Southeast Poultry Research Laboratory, 
Agricultural Research Service, US Department 
of Agriculture, 934 College Station Rd, Athens, 





To the Editor: Oropouche virus 
(OROV) is an arbovirus, Orthobu-
nyavirus, transmitted among sloths, 
marsupials, primates, and birds by the 
mosquitoes Aedes serratus and Culex 
quinquefasciatus. Notably, this virus 
has adapted to an urban cycle involving 
man, with midges (Culicoides paraen-
sis) as the main vector (1). Oropouche 
fever is the second most frequent ar-
boviral disease in Brazil, surpassed 
only by dengue. OROV causes large, 
explosive outbreaks of acute febrile 
illness in cities and villages in the Am-
azon and central regions of Brazil. An 
estimated 500,000 cases of OROV in-
fection have occurred in Brazil in the 
past 48 years. In addition to outbreaks, 
OROV can also cause sporadic human 
infections (2).
The Tropical Medicine Founda-
tion of Amazonas State (TMF-AM) 
is a tertiary care center specializing 
in tropical and infectious diseases and 
is located in the city of Manaus. Syn-
dromic surveillance for acute febrile 
illness has been conducted by TMF-
AM since 1998.  During January 2007 
through November 2008, we obtained 
blood samples from 631 patients who 
had acute febrile illness for ≥5 days 
but who had negative results at ini-
tial screening for malaria (thick blood 
smear) and dengue (MAC-ELISA). 
Blood samples were tested for OROV 
immunoglobulin (Ig) M antibodies by 
an indirect enzyme immune assay us-
ing infected cells as antigen, as previ-
ously reported for dengue (3).
For the indirect enzyme immune 
assay using infected cells as antigen, 
C6/36 A. albopictus cells were grown 
in 96 well microplates; these cells 
were infected with OROV (BeAn 1991 
strain). After 4 days, the cells were 
ﬁ  xed in the wells with 7% formalin 
buffered at pH 7.0. The microplate was 
blocked with 5% skim milk and, after 
washing the wells, 100 μL of serum 
diluted 1:400 was added into infected 
and uninfected wells. After incubation 
and washing the wells, a peroxidase-
conjugated goat anti-human IgM was 
added;  ﬁ   nally, the ABTS substrate 
(KPL, Inc., Gaithersburg, MD, USA) 
was added into the wells. The plates 
were incubated and read on a spec-
trophotometer at 405 nm. The cutoff 
for the test was determined to be the 
mean of optical densities read in all 
wells containing uninfected cells plus 
3 standard deviations.
Of the 631 patients in the study, 
128 (20.3%) had IgM antibodies to 
OROV. The age range was 2–81 years 
(mean 29.5 ± 14 years), and 77 (60.2%) 
were women or girls. Most of the cas-
es occurred November through March 
during the rainy season. In addition 
to fever, the patients had headache 
(93 [72.7%]), myalgia (90 [70.3%]), 
and arthralgia (74 [57.8%]). Rash was 
observed in 54 patients (42.2%), and 
hemorrhagic phenomena (petechiae, 
epistaxis, and gingival bleeding) were 
observed in 20 patients (15.5%). All 
patients recovered without sequelae 
and were not hospitalized.
Despite the knowledge of the oc-
currence of several arboviruses in the 
Amazon region, most cases of arbo-
viral diseases remain undiagnosed, 
probably because of their generally 
mild and self-limited clinical mani-
festations.  Patients usually recover 
completely after a couple of days. 
However, even more severe cases 
may remain undiagnosed, especially 
because of long distances to health 
care facilities, difﬁ   culties in sample 
transportation, and lack of laboratory 
facilities capable of conducting the di-
agnostic assays. With regard to OROV 
infections, diagnosis of OROV may 
be easily confused with other acute 
febrile illness, including malaria and 
dengue, both of which are highly en-
demic in Manaus.
In the present study, an inhouse 
enzyme immune assay for IgM using 
infected cell culture as antigen was 
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